B7B0DDFA-C204-4F84-A1C5-8F836668B99F
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 32.32588699080158
- age_years
- 41
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.428
- NOTCH_SIGNALING+0.403
- TGF_BETA_SIGNALING+0.392
- ADIPOGENESIS+0.348
- MITOTIC_SPINDLE+0.311
- WNT_BETA_CATENIN_SIGNALING+0.299
- INTERFERON_ALPHA_RESPONSE+0.297
- OXIDATIVE_PHOSPHORYLATION+0.251
- DNA_REPAIR+0.227
- UV_RESPONSE_DN+0.222
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.292
- KRAS_SIGNALING_DN-0.263
- SPERMATOGENESIS-0.227
- INFLAMMATORY_RESPONSE-0.214
- APICAL_SURFACE-0.167
- COAGULATION-0.145
- PANCREAS_BETA_CELLS-0.136
- KRAS_SIGNALING_UP-0.114
- APICAL_JUNCTION-0.111
- ESTROGEN_RESPONSE_LATE-0.107
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934725 | — | — | 0.856 |
| 2 | E9D4A83F-EADA-4330-911A-8F02393E0BA3 | — | — | 0.841 |
| 3 | 4099642A-F8D6-428C-AA12-1E76C27BB368 | — | — | 0.828 |
| 4 | 53BA607F-7939-40D9-BEFA-DC4ABDC7630B | — | — | 0.812 |
| 5 | 0CEC1ADC-1E8E-4CAC-8DFD-E1A760064E58 | — | — | 0.807 |
| 6 | SRR934756 | — | — | 0.806 |
| 7 | 0A7A28BA-9D46-4D4F-A0A5-B3F9AA8DF29B | — | — | 0.806 |
| 8 | SRR934762 | — | — | 0.801 |
| 9 | 443B751F-4F0B-45A1-BC83-24E446E8E573 | — | — | 0.797 |
| 10 | 7CE18C10-61E6-45FA-B9AF-408CD673C0C9 | — | — | 0.797 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.428 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.403 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.392 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.348 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.311 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.299 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.297 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.251 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.227 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.222 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.218 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.217 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.204 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.191 | Idelalisib | — uncovered |
| PEROXISOME | 0.173 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.167 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.163 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.135 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.134 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.121 | Idelalisib | — uncovered |